This is a repository copy of *Toxic shock syndrome toxin 1 evaluation and antibiotic impact in a transgenic model of staphylococcal soft tissue infection*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/154653/

Version: Published Version

**Article:**
Sharma, H., Turner, C.E. orcid.org/0000-0002-4458-9748, Siggins, M.K. et al. (4 more authors) (2019) Toxic shock syndrome toxin 1 evaluation and antibiotic impact in a transgenic model of staphylococcal soft tissue infection. mSphere, 4 (5). e00665.

https://doi.org/10.1128/msphere.00665-19

---

**Reuse**
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:
https://creativecommons.org/licenses/

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Toxic Shock Syndrome Toxin 1 Evaluation and Antibiotic Impact in a Transgenic Model of Staphylococcal Soft Tissue Infection

Hema Sharma, Claire E. Turner, Matthew K. Siggins, Mona El-Bahrawy, Bruno Pichon, Angela Kearns, Shiranee Sriskandan

Department of Infectious Disease, Imperial College London, London, United Kingdom
Department of Histopathology, Imperial College London, United Kingdom
National Infection Service, Public Health England, London, United Kingdom

ABSTRACT

Nonmenstrual toxic shock syndrome (nmTSS), linked to TSST-1-producing CC30 Staphylococcus aureus, is the leading manifestation of toxic shock syndrome (TSS). Due to case rarity and a lack of tractable animal models, TSS pathogenesis is poorly understood. We developed an S. aureus abscess model in HLA class II transgenic mice to investigate pathogenesis and treatment. TSST-1 sensitivity was established using murine spleen cell proliferation assays and cytokine assays following TSST-1 injection in vivo. HLA-DQ8 mice were infected subcutaneously with a tst-positive CC30 methicillin-sensitive S. aureus clinical TSS-associated isolate. Mice received intraperitoneal flucloxacillin, clindamycin, flucloxacillin and clindamycin, or a control reagent. Abscess size, bacterial counts, TSST-1 expression, and TSST-1 bioactivity were measured in tissues. Antibiotic effects were compared with the effects of control reagent. Purified TSST-1 expanded HLA-DQ8 T-cell Vβ subsets 3 and 13 in vitro and instigated cytokine release in vivo, confirming TSST-1 sensitivity. TSST-1 was detected in abscesses (0 to 8.0 µg/ml) and draining lymph nodes (0 to 0.2 µg/ml) of infected mice. Interleukin 6 (IL-6), gamma interferon (IFN-γ), KC (CXCL1), and MCP-1 were consistent markers of inflammation during infection. Clindamycin-containing antibiotic regimens reduced abscess size and TSST-1 production. Infection led to detectable TSST-1 in soft tissues, and TSST-1 was detected in draining lymph nodes, events which may be pivotal to TSS pathogenesis. The reduction in TSST-1 production and lesion size after a single dose of clindamycin underscores a potential role for adjunctive clindamycin at the start of treatment of patients suspected of having TSS to alter disease progression.

IMPORTANCE

Staphylococcal toxic shock syndrome (TSS) is a life-threatening illness causing fever, rash, and shock, attributed to toxins produced by the bacterium Staphylococcus aureus, mainly toxic shock syndrome toxin 1 (TSST-1). TSS was in the past commonly linked with menstruation and high-absorbency tampons; now, TSS is more frequently triggered by other staphylococcal infections, particularly of skin and soft tissue. Investigating the progress and treatment of TSS in patients is challenging, as TSS is rare; animal models do not mimic TSS adequately, as toxins interact best with human immune cells. We developed a new model of staphylococcal soft tissue infection in mice producing human immune cell proteins, rendering them TSST-1 sensitive, to investigate TSS. The significance of our research was that TSST-1 was found in soft tissues and immune organs of mice and that early treatment of mice with the antibiotic clindamycin altered TSST-1 production. Therefore, the early treatment of patients suspected of having TSS with clindamycin may influence their response to treatment.

Citation Sharma H, Turner CE, Siggins MK, El-Bahrawy M, Pichon B, Kearns A, Sriskandan S. 2019. Toxic shock syndrome toxin 1 evaluation and antibiotic impact in a transgenic model of staphylococcal soft tissue infection. mSphere 4:e00665-19. https://doi.org/10.1128/mSphere.00665-19.

Editor Paul D. Fey, University of Nebraska Medical Center
Copyright © 2019 Sharma et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Address correspondence to Hema Sharma, h.sharma@imperial.ac.uk, or Shiranee Sriskandan, s.sriskandan@imperial.ac.uk.
* Present address: Claire E. Turner, University of Sheffield, Sheffield, United Kingdom.

Clindamycin reduces TSST-1 production in humanized transgenic mouse model of staphylococcal skin infection @grampospath
Received 17 September 2019
Accepted 22 September 2019
Published 9 October 2019
Staphylococcal toxic shock syndrome (TSS) is a potentially lethal illness characterized by fever, rash, desquamation, organ dysfunction, and shock. The syndrome is attributed to superantigens produced by *Staphylococcus aureus*, in particular, toxic shock syndrome toxin 1 (TSST-1). TSST-1 has been associated with almost all menstrual TSS (mTSS) and half of nonmenstrual TSS (nmTSS) cases (1), while staphylococcal enterotoxins A, B, and C (SEA, SEB, and SEC) are implicated in the remaining nmTSS cases (2, 3). Superantigens bind simultaneously to the HLA class II molecule on antigen-presenting cells and the T-cell receptor, causing massive T-cell activation, expansion, and cytokine release (2). In the United Kingdom, nmTSS is now more common than mTSS. Skin and soft tissue infections (SSTI) are the most frequent trigger for nmTSS, which, in the United Kingdom, is associated with TSST-1-producing strains in 41% of cases (4). Due to its rarity, TSS pathogenesis is poorly understood, and there is a paucity of clinical data to guide treatment choices. Notwithstanding a lack of clinical trial or *in vivo* data, combination antimicrobial treatment with β-lactams and protein synthesis inhibitors is recommended for staphylococcal TSS (5), based solely upon *in vitro* studies and extrapolation from observational studies of streptococcal TSS.

Murine models of TSS may provide insight into TSS pathogenesis and antimicrobial efficacy but are hampered by low-affinity interactions between murine major histocompatibility class II (MHC II) and staphylococcal superantigens. Prior sensitization with lipopolysaccharide (6) or α-galactosamine (7) has been used to induce superantigen-mediated lethality, though the pathological changes incurred may differ markedly from those induced by superantigen alone. Transgenic expression of human HLA class II can render mice superantigen sensitive and allows investigation of superantigen-associated inflammation without the need for sensitization (8), removing potential experimental confounders. There are few recent studies of staphylococcal TSS infection using contemporary clinical strains and none that evaluate disease progression and toxin release in superantigen-sensitive mice. We developed a humanized transgenic model of superantigen-associated SSTI using a clinical TSST-1-producing CC30 methicillin-sensitive *S. aureus* (MSSA) TSS-associated isolate to investigate the pathogenesis and treatment of nmTSS.

This work was presented in part at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, in September 2015.)

RESULTS

**HLA-DQ8 transgenic mice are superantigen and TSST-1 sensitive.** The proliferation of mouse spleen cells in response to superantigens was assessed to determine the superantigen sensitivity of transgenic mice in comparison to that in wild-type mice to recapitulate human immune responses to superantigens, such as those which occur in TSS. Spleen cells of HLA-DQ8 transgenic mice were markedly more sensitive to purified TSST-1 than spleen cells from wild-type C57BL/6 mice (Fig. 1A). Indeed, HLA-DQ8 spleen cells were more sensitive to all staphylococcal superantigens tested than cells from either HLA-DR4 or wild-type mice (see Fig. S2 in the supplemental material). Because of this, all further experiments were performed using HLA-DQ8 mice.

The response of HLA-DQ8 splenocytes to superantigens was compared to that of human peripheral blood mononuclear cells (PBMCs). HLA-DQ8 mice were sensitive to TSST-1 at micromolar concentrations and to SEB at nanomolar concentrations. Human PBMCs were sensitive at picomolar concentrations to both superantigens (Fig. S3).

Following coculture, TSST-1 expanded HLA-DQ8 mouse spleen cell T-cell receptor (TCR) Vβ subsets TCR Vβ3 and TCR Vβ13 (Fig. 1B). HLA-DQ8 mice treated with TSST-1 intraperitoneally (i.p.) had elevated levels of the serum cytokines interleukin 6 (IL-6), KC (CXCL1), IL-12p70, IL-17, and MCP-1 at 2 h and gamma interferon (IFN-γ) at 6 h
FIG 1  HLA-DQ8 mice are superantigen sensitive. (A) Sensitivities of HLA-DQ8 and C57BL/6 splenocytes to TSST-1. Splenocytes (1 × 10^6/ml) from HLA-DQ8 and C57BL/6 mice were exposed to 0 to 10 μg/ml of TSST-1. Proliferation was measured by [3H]thymidine uptake. CPM, counts per minute. Proliferation in the presence of 5 μg/ml concanavalin (positive control) was 229,806 ± 48,570 CPM for C57BL/6 spleen cells and 373,349 ± 56,008 CPM for HLA-DQ8 spleen cells. Data are means ± SD of results from three individual mice. *, P < 0.05; **, P < 0.01 between HLA-DQ8 and C57BL/6 by ANOVA. (B) Percentages of spleen cells from HLA-DQ8 mice in each CD3+/ TCR Vβ subset expanded by TSST-1. Spleen cells (1 × 10^6/ml) were labeled with CellTrace far-red proliferation dye (CTFR) and stimulated with 2.5 μg/ml TSST-1, 2.5 μg/ml concanavalin A (positive control), or left unstimulated (negative control). Bars show means ± SD of results for 3 mice. ****, P < 0.0001 between TSST-1 and unstimulated splenocytes by two-way ANOVA. (C) Serum cytokines 2 h and 6 h after i.p. injection of 80 μg TSST-1 in HLA-DQ8 or C57BL/6 mice. Values to the right of the dashed line refer to the y axis on the right. Medians and 5th, 25th, 50th, 75th, and 95th centiles for five individual mice are shown. *, P < 0.05 by Mann-Whitney U test between HLA-DQ8 and C57BL/6 mice treated with TSST-1. IFNγ, gamma interferon; IL-6, interleukin 6; IL12p70, interleukin 12 (p70); IL-17, interleukin 17; KC, CXCL1; MCP-1, monocyte chemotactic protein 1.
compared to levels in wild-type C57BL/6 control mice (Fig. 1C). Levels of other cytokines tested did not differ between groups (Table S2).

**Modeling soft tissue infection in HLA-DQ8 mice.** Having demonstrated responsiveness to TSST-1, HLA-DQ8 transgenic mice were infected subcutaneously (s.c.) with TSST-1-producing *S. aureus*, and groups were euthanized at 24, 48, and 72 h. By 24 h, there was visible abscess formation at the inoculation site. Abscess volume and bacterial load decreased by 72 h. Bacteria disseminated to the spleen at all time points in 17/18 mice, though spleen bacterial loads decreased during infection. Two to three mice in each group had detectable bacteremia at each time point (Fig. 2). Weight loss was maximal 24 h following infection (median, 9.3%; range, 0 to 15.9%).

**tst** mRNA transcripts in pus obtained from the abscess were detectable in 5/6 mice at 24 h, 1/6 mice at 48 h, and 2/6 mice at 72 h and were maximal at 24 h (Fig. 3A). Due to the use of abscess samples for RNA and other analyses, measurement of TSST-1 protein was undertaken for just one mouse at each time point; TSST-1 protein was, however, detected by Western blotting in the 24-h pus sample (8 μg/ml) but not at 48 or 72 h. Human PBMCs were sensitive to TSST-1 at nanomolar concentrations (Fig. 3B). Pus recovered from abscesses demonstrated sustained mitogenic activity toward human PBMCs at 24 and 48 h, but not at 72 h, when diluted 1:100. Strong mitogenic activity toward human PBMCs was also detected in all sera at 24 h despite infrequent bacteremia, consistent with the presence of superantigen in the mouse serum (Fig. 3C and D).

Serum cytokines and chemokines were maximal 24 h postinfection, consistent with the findings of purified TSST-1 challenge. IL-6, IFN-γ, KC, MCP-1, MIP-1α, and granulo-
cyte colony-stimulating factor (G-CSF) were raised in infected transgenic mice, unlike with control HLA-DQ8 mice inoculated with phosphate-buffered saline (PBS) alone (Table S3).

On histological analysis of abscess sections from single mice, bacteria were detected on each day of infection, accompanied by heavy subcutaneous infiltration by neutrophils, with inflammation (Fig. S4).

Draining lymph node involvement during *S. aureus* infection. To determine whether *S. aureus* infection involved draining inguinal lymph nodes, four HLA-DQ8 mice infected with the CC30 tst-positive *S. aureus* strain HSS357 were euthanized 24 h following infection and dissected, with careful removal of inguinal lymph nodes. Bacteria were detected in the subcutaneous abscess (median, $1.3 \times 10^7$ CFU; range, 0 to 2.8 $\times 10^7$ CFU/abscess), the ipsilateral inguinal lymph node (median, 8.5 CFU; range, 0 to 1.4 $\times 10^4$ CFU/lymph node), and spleen (median, 4.0 $\times 10^{-1}$ CFU; range, 2.0 $\times 10^{-5}$ to 2.6 $\times 10^3$ CFU/mg spleen), but not the contralateral inguinal lymph node or blood. The greatest bacterial burden was in the subcutaneous abscess, but there was also abscessation in the ipsilateral inguinal lymph nodes of all mice. TSST-1 was detected at the highest level in pus from the subcutaneous abscesses of all four mice and was detected in the ipsilateral inguinal lymph nodes from 2/4 mice but not in any contralateral inguinal lymph node (Fig. 4A). Mitogenicity was elicited (in descending order of magnitude) from the subcutaneous abscess pus, ipsilateral inguinal lymph nodes,
Antibiotic impact on lesion size and superantigen toxin production. *S. aureus*-infected HLA-DQ8 mice were treated with a single dose of flucloxacillin (FCX), clindamycin (CLD), FCX-CLD, or sterile PBS at 24 h postinfection and were euthanized at 30 h, i.e., 6 h after antibiotic or PBS administration, to assess the impact of antibiotics on TSST-1 production and the host immune response. Within 6 h of antibiotic administration, mice treated with CLD-containing regimens had smaller abscesses and reduced local TSST-1 production compared to those of mice treated with PBS or FCX alone (Fig. 5A and B). Accordingly, there was a clear reduction in pus and serum sample mitogenicity (Fig. 5C and D). The pus sample was not subjected to quantitative real-time PCR (qRT-PCR) of tst transcripts due to previously low levels of transcript detection.

Cytokine differences between control and antibiotic-treated groups were negligible; however, the level of IL-2 was reduced in mice treated with CLD-containing regimens compared to those in mice treated with PBS or FCX, consistent with reduced T-cell stimulation (Fig. 6). The single antibiotic dose did not impact the numbers of CFU detected in the abscess, lymphoid organs, or blood compared with those detected in mice given PBS (Fig. 7). In particular, CLD did not confer any additional benefit with regard to bacteriological clearance during this short treatment time.

**DISCUSSION**

We describe an *S. aureus* subcutaneous-abscess model in HLA-DQ8 transgenic mice. These mice demonstrated sensitivity to TSST-1, which expanded the murine T-cell receptor Vβ subsets TCR Vβ3 and TCR Vβ13. *S. aureus* disseminated to the draining inguinal lymph nodes and spleen, while TSST-1 production was detected in not only the subcutaneous abscess but also the draining inguinal lymph node, signaled by mitogenic activity in the abscess pus, the ipsilateral inguinal lymph node, and serum. Clindamycin-containing antibiotic regimens reduced abscess volume, TSST-1 production, and the overall mitogenic activity of the lesion within just 6 h of a single treatment.

Experimental comparison of infections with different strains of transgenic mice was not possible in this study. It was notable that HLA-DQ8 mice appeared to be more sensitive to TSST-1 than HLA-DR4 mice *in vitro*, despite previous work indicating that TSST-1 binds to HLA-DR molecules with levels of affinity greater than (9) or equal to (10) its levels of affinity to HLA-DQ molecules. Polymorphisms in HLA-DR are also known to
affect transgenic-mouse responses to TSST-1 (11). It is likely that differential expression of the HLA transgenes and endogenous H2 or responding T-cell subset repertoires may explain the enhanced responses in HLA-DQ8 mice, as we noted that responsiveness to concanavalin A (ConA) and medium alone was also greater in HLA-DQ8 mice. Nevertheless, infection with a CC30 S. aureus isolate that produces a high level of TSST-1 led to marked suppuration, abscess formation, and cytokine production.

FIG 5 Antibiotics impact abscess volume, TSST-1 production, and mitogenicity during infection with TSST-1-producing S. aureus in HLA-DQ8 mice. HLA-DQ8 mice were infected subcutaneously with tst-positive CC30 MSSA strain HSS357 (1 × 10⁹ CFU). At 24 h, mice received fluocoxacinil, clindamycin, fluocoxacinil and clindamycin, or 100 μl PBS i.p. (as a control) and were culled at 30 h. (A) Abscess dimensions were measured. (B) TSST-1 protein present in abscesses was measured by Western blotting. TSST-1 protein of known concentration was also measured to quantify the amount of TSST-1 by densitometry. (C and D) Human PBMC responses to pus (C) and serum (D) from infected mice were measured. Proliferation was measured by BrdU uptake. Negative, tissue culture medium (RPMI 1640) alone. Medians and 5th, 25th, 50th, 75th, and 95th centiles are shown for five individual mice. *, P < 0.05; **, P < 0.01 by Mann-Whitney U test comparing different antibiotic regimens with the control.

FIG 6 Interleukin-2 levels after antibiotic administration to HLA-DQ8 mice infected with TSST-1-producing S. aureus. HLA-DQ8 mice were infected subcutaneously with tst-positive S. aureus strain HSS357 (1 × 10⁹ CFU). At 24 h, mice received fluocoxacinil, clindamycin, fluocoxacinil and clindamycin, or 100 μl PBS i.p. (as a control) and were culled at 30 h. Serum was collected by cardiac puncture and analyzed by immunoassay. Medians and 5th, 25th, 50th, 75th, and 95th centiles are shown for five individual mice. *, P < 0.05; **, P < 0.01 by the Mann-Whitney U test compared to control mice injected with PBS alone.
We believe that the suppuration observed was in part related to TSST-1 responsiveness. It was not possible to evaluate an isogenic, tst-deficient strain to determine which of the observed effects were due solely to TSST-1; the CC30 lineage of S. aureus is challenging to transform, although recent tools may now allow for its manipulation (12). HSS357 carried (aside from tst) sei and seg, which are found in the enterotoxin gene cluster (egc). The egc gene cluster is widespread in S. aureus strains (13) and unlikely to have any specific association with TSS.

The measurement of TSST-1 production in vivo provides valuable contextual information to inform future superantigen research. In some experiments, we detected higher levels of TSST-1 in subcutaneous abscess pus than could be detected during broth culture of the same strain (4) and higher levels than previously reported in the abscesses and kidney extracts of mice infected with TSST-1-producing S. aureus (14, 15), consistent with upregulation of superantigen production during suppurative infection. Microbial spread and suppuration were noted in the ipsilateral inguinal lymph node, a tissue rich in superantigen-sensitive T cells, and TSST-1 protein was detected here too 24 h after infection. The detection of bacteria and TSST-1 in ipsilateral, but not contralateral, inguinal nodes is consistent with transit in afferent lymphatic vessels rather than blood. During infection, abscessation was present in all the ipsilateral

FIG 7  Bacteriology of the antibiotic impact on HLA-DQ8 mice infected with TSST-1-producing S. aureus. HLA-DQ8 mice were infected subcutaneously with tst-positive S. aureus strain HSS357 (1 x 10^9 CFU). At 24 h, mice received fluclaxacinilin, clindamycin, fluclaxacinilin and clindamycin, or 100 μl PBS i.p. (as a control) and were culled at 30 h. (A) Abscess pus was extracted and plated for CFU counting; (B and C) ipsilateral/contralateral inguinal lymph nodes (LN) were excised, homogenized, and plated for CFU counting; (D) spleens were extracted, homogenized, and plated for CFU counting; (E) blood cultures were taken by cardiac puncture. Data and medians are shown for 5 individual mice per group.
inguinal lymph nodes, including those without detectable viable bacteria, as *S. aureus* may have been killed by the neutrophils creating the pus. We cannot determine whether TSST-1 was produced within the lymph node by *S. aureus* or transferred from the site of infection via lymphatics. The proximity of TSST-1-producing *S. aureus* to such lymphoid tissues may be pivotal to events occurring during TSS; the extent to which this occurs in clinical disease is unknown. It is widely believed that TSS results from the systemic dissemination of superantigens into the bloodstream and consequent interaction with leukocytes in the lympho-reticular system; in mice, the spleen is known to act as a major source of cytokines following systemic superantigen administration (16). Our results raise the possibility that superantigen exposure within secondary lymphoid organs, such as the lymph nodes, may contribute to the cytokine storm underlying TSS pathogenesis during infection. Previous studies using HLA transgenic mice have reported IL-6, IFN-γ, and IL-2 serum responses in HLA-DQ8 mice exposed to aerosolized SEB (17) and IL-6 and IFN-γ production by HLA-DR3 spleen cells exposed to SEB (18). We detected cytokine responses to a bolus of toxin and to infection; IL-6, IFN-γ, KC, and MCP-1 were the most consistent markers of inflammation.

Lethal shock was not observed or expected in this model; we note that sensitization agents were not used and that bacterial clearance occurred over the 72-h experimental period. Thus, this model does not replicate TSS as observed in humans but served to elucidate potential pathways of TSST-1 production, dissemination, and abscess progression in a model that reproduces some of the immunological responses to staphylococcal infection seen in humans. Previous models of TSS in HLA-DR1 mice required d-galactosamine pretreatment to elicit liver failure, an event that is entirely related to tumor necrosis factor (TNF)-induced hepatocyte apoptosis in the d-galactosamine setting, while SEB alone results in cytokine release only (16). Changes in serum cytokine levels were observed in both HLA-DQ6 and HLA-DQ8 mice at 4 h following SEB and streptococcal pyrogenic exotoxin A (SPEA) challenge (19). In our study, weight loss, *tst* transcripts, TSST-1 protein, and cytokines were maximal at 24 h following infection, consistent with a marked systemic inflammatory response that might be like that observed in nmTSS.

TSST-1 expanded TCR Vβ subsets 3 and 13 in HLA-DQ8 mouse splenocytes. TSST-1-induced TCR Vβ15 and -17 subset expansion, as was previously reported in earlier murine studies, could not be evaluated in the current study, as the assay used did not detect them (20, 21). Further work to determine whether TSST-1 results in specific T-cell Vβ subset expansion and cytokine release within lymphoid organs in the context of *S. aureus* infection would provide novel insight into nmTSS pathogenesis.

Notwithstanding findings in local lymph nodes, the mitogenicity assays strongly pointed to the presence of superantigen in the sera of infected mice. While we could not directly quantify TSST-1 in serum, parallel standard TSST-1 bioactivity assays yielded data suggesting that 1 to 10 pg/ml of TSST-1 was present in the blood. TSST-1 at 0.2 pg/ml is reported to cause half-maximum proliferation of human T cells (2). We cannot rule out the possibility that low levels of *S. aureus* were present in the blood (limit of detection, 200 CFU/ml). However, the absence of a detectable bacteremia supports the assertion that TSST-1 may disseminate from the initial infection site to systemic circulation either by transcytosis across cellular barriers to reach the blood (22) or via the lymphatic system, enabling activation of T cells distant to the site of infection.

Current TSS treatment recommendations advise a combination of β-lactam and lincosamide antibiotics, until culture results are known (5). This is based on *in vitro* studies, extrapolation from observational studies of streptococcal TSS, and *in vivo* evaluations of the effects of protein synthesis inhibitors in rabbit models of pneumonia using Panton-Valentine leukocidin-producing *S. aureus* (23). There is a lack of published *in vivo* data on the effect of clindamycin on TSST-1 production in any infection model. We elected to evaluate this effect and whether using clindamycin at the outset of TSS management might impact disease progression. We chose to treat a time point when *tst* transcripts and TSST-1 protein were maximal and cytokines detectable. Unsurprisingly, a single dose of antibiotic did not reduce abscess bacterial burden,
consistent with previous findings (24). Notably, however, mice treated with clindamycin-containing regimens had smaller abscesses, reduced TSST-1 production, and diminished mitogenicity of pus and serum compared to those of mice treated with other regimens. This is the first work to demonstrate the superantigen-inhibitory effects of clindamycin in vivo. The findings suggest that clindamycin may have an indirect effect on disease and abscess progression, potentially by reducing TSST-1 synthesis, despite little measurable effect on bacterial counts by this model. Previous reports do suggest that abscessation may be enhanced by superantigens; hepatic abscesses are known to develop in HLA transgenic mice exposed to SEA-producing S. aureus (25). Although clindamycin can exert an inhibitory effect on superantigen-induced host cytokine production in vitro (26), serum cytokine levels in our study did not demonstrate a clear antibiotic effect, perhaps due to the timing of analysis following one antibiotic dose.

Our findings support the adjunctive use of clindamycin to modify disease progression in the treatment of suspected staphylococcal TSS, to reduce superantigen toxification production more rapidly, and to potentially reduce abscessation. Further studies are required to increase our understanding of TSS pathogenesis and the role of lymph node superantigen expression and to explore the efficacy of treatment with other immune modulators, such as intravenous immunoglobulin, to limit the lethal potential of this syndrome.

MATERIALS AND METHODS

Animals. Female HLA class II transgenic mice on a C57BL/6 background carrying genomic constructs for HLA-DQA1*0301/HLA-DQB*0302 (DQB), HLA-DRB1*0101/HLA-DRB1*0401 (DR4, H2 Aj10; Taconic Farms) (8, 27, 28), and C57BL/6 mice (Charles River, UK) that were 8 to 14 weeks old were used in accordance with a UK Home Office-approved project license following assessment by the Imperial College Ethical Review Process. Mice were acclimatized for 1 week prior to use.

Bacterial culture. HSS357, a clinical tst-positive CC30 MSSA strain that caused TSS, was selected based on highest in vitro TSST-1 production (187 ng/ml following overnight culture in 5 ml of brain heart infusion [BHI] broth) among clinical tst-positive CC30 MSSA isolates causing TSS (4). Overnight culture of strain HSS357 in 50 ml BHI yielded 400 ng/ml of TSST-1, although transcription of tst peaked at 8 h and diminished thereafter (see Fig. S1 in the supplemental material). HSS357 was sensitive to all antibiotics, including clindamycin and flucloxacillin, with the exception of penicillin. Antibiotic MICs were determined with anti-CD3

viability dye, and (iv) acquired on a FACSCalibur flow cytometer. Live CD3

infusion [BHI] broth) among clinical

mitogenicity of pus and serum compared to those of mice treated with other regimens. This is the first work to demonstrate the superantigen-inhibitory effects of clindamycin in vivo. The findings suggest that clindamycin may have an indirect effect on disease and abscess progression, potentially by reducing TSST-1 synthesis, despite little measurable effect on bacterial counts by this model. Previous reports do suggest that abscessation may be enhanced by superantigens; hepatic abscesses are known to develop in HLA transgenic mice exposed to SEA-producing S. aureus (25). Although clindamycin can exert an inhibitory effect on superantigen-induced host cytokine production in vitro (26), serum cytokine levels in our study did not demonstrate a clear antibiotic effect, perhaps due to the timing of analysis following one antibiotic dose.

Our findings support the adjunctive use of clindamycin to modify disease progression in the treatment of suspected staphylococcal TSS, to reduce superantigen toxification production more rapidly, and to potentially reduce abscessation. Further studies are required to increase our understanding of TSS pathogenesis and the role of lymph node superantigen expression and to explore the efficacy of treatment with other immune modulators, such as intravenous immunoglobulin, to limit the lethal potential of this syndrome.
Mice were euthanized at various time points postinfection, blood was taken by cardiac puncture for CFU quantification, and sera were collected and stored at −20°C. Abscess dimensions (height, width, and depth) were measured by a single observer using a mini-Vernier caliper for all experiments. Pus was excised by forceps at the time of dissection and stored in sterile Tris-EDTA buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA). Aliquots of pus were taken for bacterial quantification, storage at −20°C for cytokine analysis and mitogenicity assays. Spleens and left and right inguinal lymph nodes were homogenized in sterile PBS for CFU quantification, and lymph nodes were stored at −20°C for ex vivo mitogenicity testing.

Expression of tst in vitro and in vivo. One microgram of cDNA was synthesized from bacterial RNA treated with Turbo DNase (Ambion; Thermo Fisher) with Transcripter reverse transcriptase (Roche, Basel, Switzerland) and random hexamer primers (Sigma, Dorset, UK). Quantitative real-time PCR (qRT-PCR) was performed using PCR primers for tst and the housekeeping gene rrsA (Table S1) with SYBR green JumpStart Taq ReadyMix (Sigma). Transcript copies were calculated by comparison with standard 10-fold concentrations of plasmid pCR2.1 (Invitrogen, Hemel Hempstead, UK) containing single copies of target genes (tst or rrsA) amplified alongside bacterial cDNA. Numbers of copies of sample tst transcripts were normalized to 10,000 copies of rrsA.

Detection of TSST-1 by Western blotting. Proteins were separated by 10% Bolt Bis-Tris Plus gel, transferred to nitrocellulose (Amersham Protran, GE Healthcare, Amersham UK), blocked, and then probed after incubation with rabbit anti-TSST-1 polyclonal antibody (Abcam, Cambridge, UK) and anti-rabbit horseradish peroxidase (HRP)-conjugated antibody (Life Technologies, Hemel Hempstead, UK) with an ECL Plus substrate detection system (Life Technologies). TSST-1 concentration in samples was determined by comparison with standard concentrations of TSST-1 simultaneously analyzed by densitometry (LabWorks, UVP, CA, USA). Samples below the detection limit were assigned half the value of the lowest standard concentration detected.

Human T-cell proliferation assay. Normal donor peripheral blood mononuclear cells (PBMCs) from anonymized consenting healthy donors were obtained from an approved subcollection of the Imperial College NHS Trust Tissue Bank (ICHBT reference R12023). PBMCs (1 × 10⁶/ml) were incubated in RPMI 1640 medium (Life Technologies) containing 10% fetal calf serum, 2 mM glutamine, and 50 U/ml of penicillin and streptomycin with a 1:100 dilution of murine pus or mouse serum at 37°C for 48 h. All measurements were performed as technical replicates in triplicate. T-cell proliferation was measured after incorporation of 1.0 μCi/well of [³²P]thymidine and an additional 16 h of incubation or after T cells were labeled with 10 μM of BrdU (Roche, Welwyn Garden City, UK) and incubated for a further 4 h. The BrdU proliferation assay was used in place of [³²P]thymidine incorporation during the study due to changes in the use of radioisotopes within the laboratory.

Cytokine, chemokine, and growth factor measurement. Serum cytokines were measured on a Bio-Rad Bio-Plex Luminex 200 system using a mouse 23-plex panel (Bio-Rad, CA, USA) that analyzed eotaxin, G-CSF, granulocyte macrophage CSF (GM-CSF), IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17A, KC, MCP-1, MIP-1α, MIP-1β, RANTES, and TNF-α. For analysis, samples below the detection limit were assigned half the value of the lowest level detected.

Histopathology. Tissue was dissected from randomly selected single HLA-DQ8 mice at each infection time point and fixed in formalin. Paraffin-embedded tissues were stained with hematoxylin and eosin or Gram’s stain and reviewed in a blind manner by a histopathologist (M. El-Bahrawy).

Statistical analysis. Data were stated as medians (ranges) or means ± standard deviations (SD). Data were analyzed with GraphPad Prism 6.0 (GraphPad Software, CA, USA) using analysis of variance (ANOVA), the Mann-Whitney U test, or an unpaired t test (two tailed) as indicated in the figure legends. Probability values of <0.05 were considered significant based on a two-tailed test.

SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mSphere.00665-19.

FIG S1, TIF file, 0.1 MB.
FIG S2, TIF file, 0.3 MB.
FIG S3, TIF file, 0.1 MB.
FIG S4, TIF file, 1 MB.
TABLE S1, DOCX file, 0.02 MB.
TABLE S2, DOCX file, 0.03 MB.
TABLE S3, DOCX file, 0.03 MB.

ACKNOWLEDGMENTS
We acknowledge D. Kioussis and R. A. Flavell for transgenic mice and D. M. Altmann for access, and we thank Nur S. C. Ahmad for technical contributions.

We acknowledge support from the NIHR Biomedical Research Centre (BRC) to the Imperial College Healthcare Trust and the NIHR BRC-funded Tissue Bank. This work was also supported by the UK Clinical Research Collaboration through a research training fellowship (G0800777/1 to H.S.). We have no conflicts of interest to declare.
REFERENCES

1. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. 1990. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 17:251–272. https://doi.org/10.3109/10408419091075726.

2. Fraser JD, Profitt T. 2008. The bacterial superantigen and superantigen-like proteins. Immunol Rev 225:226–243. https://doi.org/10.1111/j.1600-065X.2008.00681.x.

3. Whiting JL, Rosten PM, Chow AW. 1989. Determination by Western blot (immunoblot) of seroconversions to toxic shock syndrome (TSS) toxin 1 and enterotoxin A, B, or C during infection with TSS- and non-TSS-associated Staphylococcus aureus. Infect Immun 57:231–234.

4. Sharma H, Smith D, Turner CE, Game L, Pichon B, Hope R, Hill R, Kearns A, Sriskandan S. 2018. Clinical and molecular epidemiology of staphylococcal toxic shock syndrome in the United Kingdom. Emerg Infect Dis 24:258–266. https://doi.org/10.3202/eid2402.170606.

5. American Academy of Pediatrics. 2015. Staphylococcal infections, p 715–732. In Kimberlin DW, Brady MT, Jackson MA, Long SS (ed). Red book: 2015 report of the Committee on Infectious Diseases. American Academy of Pediatrics, Elk Grove Village, IL.

6. Dinges MM, Schlievert PM. 2001. Comparative analysis of lipopolysaccharide-induced tumor necrosis factor alpha activity in serum and lethality in mice and rabbits pretreated with the staphylococcal superantigen toxic shock syndrome toxin 1. Infect Immun 69:7169–7172. https://doi.org/10.1128/IAI.69.11.7169-7172.2001.

7. Faulkner L, Altmann DM, Ellmerich S, Huhtaniemi I, Stamp G, Sriskandan S, Krogmann A, Tilahun A, David CS, Krakauer T, Bavari S. 2005. Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B. Infect Immun 73:2452–2460. https://doi.org/10.1128/IAI.73.4.2452-2460.2005.

8. DaSilva L, Welcher BC, Ulrich RG, Aman MJ, David CS, Bavari S. 2002. Humanlike immune response of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines. J Infect Dis 185:1754–1760. https://doi.org/10.1086/340828.

9. Rajagopalan G, Polich G, Sen MM, Singh M, Epstein BE, Lytle AK, Rouse MS, Patel R, David CS. 2008. Evaluating the role of HLA-DQ polymorphisms on tumor response to staphylococcal superantigenic mouse. Tissue Antigens 71:135–145. https://doi.org/10.1111/j.1399-0039.2007.00986.x.

10. Marrack P, Kappler J. 1990. The staphylococcal enterotoxins and their relatives. Science 248:1066. https://doi.org/10.1126/science.248.4959.1066-b.

11. Callahan JE, Herman A, Kappler JW, Marrack P. 1990. Stimulation of B10.BR T cells with superantigenic staphylococcal toxins. J Immunol 144:2473–2479.

12. Hamad AR, Marrack P, Kappler JW. 1997. Transcytosis of staphylococcal superantigen toxins. J Exp Med 185:1447–1454. https://doi.org/10.1084/jem.185.8.1447.

13. Croisier-Bertin D, Hayez D, Da Silva S, Labrousse D, Blek D, Badiou C, Dumitrescu O, Guerard P, Charles PE, Piroth L, Lina G, Vandenfes S, Chavaret P. 2014. In vivo efficacy of cefartanome fosamil in a methicillin-resistant Panton-Valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model. Antimicrob Agents Chemother 58:1855–1861. https://doi.org/10.1128/AAC.01707-13.

14. Turner CE, Sriskandan S. 2015. Panton-Valentine leucocidin expression by Staphylococcus aureus exposed to common antibiotics. J Infect 71:338–346. https://doi.org/10.1016/j.jinf.2015.05.008.

15. Xu SX, Gilmore KJ, Szabo PA, Zeppa JJ, Baroja ML, Haeryf H, McNearney CL, Krakauer T, Bavari S. 2014. Superantigens subvert the neutrophil response to staphylococcal enterotoxin B of Staphylococcus aureus and enhance Staphylococcus aureus survival in vivo. Infect Immun 82:3588–3598. https://doi.org/10.1128/IAI.02110-14.

16. Pichereau S, Moran JJ, Haynes M, Shukla SK, Sakoulos G, Rose WE. 2012. Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells. J Antimicrob Chemother 67:123–129. https://doi.org/10.1093/jac/dkr417.

17. Hu SC, Bian HJ, Molina M, Han J, Magram J, Saar E, Beluns C, Bolin DR, Arceo R, Campbell R, Falcioni F, Vidovic D, Hammer J, Nagy ZA. 1996. HLA-DR4-B10.BR T cells with superantigenic staphylococcal toxins. J Immunol 157:2635–2644. https://doi.org/10.1084/jem.183.6.2635.

18. Wen L, Wong FS, Burkly L, Alieteri M, Mamalaki C, Kioussis D, Flavell RA, Shervin RS. 1998. Induction of insults by glutamic acid decarboxylase peptide-specific and HLA-DQ8-restricted CD4(+) T cells from human DQ transgenic mice. J Clin Invest 102:947–957. https://doi.org/10.1172/JCI2723.

19. Milheiro P, Oliveira DC, de Lencastre H. 2014. Update to the multiplex PCR strategy for assignment of mec element types in Staphylococcus aureus. Antimicrob Agents Chemother 51:3374–3377. https://doi.org/10.1128/AAC.00275-07.

20. Boakes E, Kearns AM, Garner M, Perry C, Warner M, Hill RL, Ellington MJ. 2011. Molecular diversity within clonal complex 22 methicillin-resistant Staphylococcus aureus encoding Panton-Valentine leukocidin in England and Wales. Clin Microbiol Infect 17:140–145. https://doi.org/10.1111/j.1469-0691.2010.03199.x.

21. Turner CE, Kurupati P, Jones MD, Edwards RJ, Sriskandan S. 2009. Emerging role of the interleukin-8 cleaving enzyme SpyCEP in clinical Strep-tococcus pyogenes infection. J Infect Dis 200:555–563. https://doi.org/10.1086/603541.